

NASH and cryptogenic cirrhosis: A histological analysis

Annals of Hepatology

8, 346-352

DOI: [10.1016/s1665-2681\(19\)31748-x](https://doi.org/10.1016/s1665-2681(19)31748-x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Cryptogenic Cirrhosis: What Are We Missing?. <i>Current Gastroenterology Reports</i> , 2010, 12, 40-48.	1.1	39
2	Prevalence of non alcoholic fatty liver disease in premenopausal, postmenopausal and polycystic ovary syndrome women. The role of estrogens. <i>Annals of Hepatology</i> , 2010, 9, 402-409.	0.6	192
4	Frequency and Outcomes of Liver Transplantation for Nonalcoholic Steatohepatitis in the United States. <i>Gastroenterology</i> , 2011, 141, 1249-1253.	0.6	1,006
7	Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 1536-1543.	1.4	145
8	Cryptogenic Chronic Hepatitis and Its Changing Guise in Adults. <i>Digestive Diseases and Sciences</i> , 2011, 56, 3421-3438.	1.1	46
9	Endpoints and clinical trial design for nonalcoholic steatohepatitis. <i>Hepatology</i> , 2011, 54, 344-353.	3.6	617
10	Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. <i>International Journal of Cancer</i> , 2011, 128, 2436-2443.	2.3	425
11	Non-alcoholic fatty liver disease: what's new under the microscope?. <i>Gut</i> , 2011, 60, 1152-1158.	6.1	31
12	Fatty liver index in polycystic ovary syndrome. <i>European Journal of Endocrinology</i> , 2011, 165, 935-943.	1.9	49
13	Cirrose hepática revisitada – a propósito de um caso clínico. <i>GE Jornal Português De Gastreenterologia</i> , 2012, 19, 209-214.	0.0	0
14	Development and validation of a new histological score for pediatric non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2012, 57, 1312-1318.	1.8	72
15	Fatty liver disease. , 2012, , 293-359.		16
16	Histological assessment of nonalcoholic fatty liver disease in adults and children. <i>Clinical Liver Disease</i> , 2012, 1, 108-111.	1.0	26
17	Alcohol's Effect on Other Chronic Liver Diseases. <i>Clinics in Liver Disease</i> , 2012, 16, 827-837.	1.0	21
18	Autoantibody-Negative Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , 2012, 57, 610-624.	1.1	75
19	Autophagy Deficiency by Hepatic FIP200 Deletion Uncouples Steatosis From Liver Injury in NAFLD. <i>Molecular Endocrinology</i> , 2013, 27, 1643-1654.	3.7	95
20	NAFLD in Asia – as common and important as in the West. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013, 10, 307-318.	8.2	377
23	Effects of Indoleamine 2,3-Dioxygenase Deficiency on High-Fat Diet-Induced Hepatic Inflammation. <i>PLoS ONE</i> , 2013, 8, e73404.	1.1	53

#	ARTICLE	IF	CITATIONS
24	Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. <i>World Journal of Gastroenterology</i> , 2014, 20, 15539.	1.4	310
25	Non-alcoholic fatty liver disease and thyroid dysfunction: A systematic review. <i>World Journal of Gastroenterology</i> , 2014, 20, 8102.	1.4	113
27	Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S.. <i>Hepatology</i> , 2014, 59, 2188-2195.	3.6	616
28	Hepatocellular carcinoma with steatohepatitic features: a clinicopathological study of Japanese patients. <i>Histopathology</i> , 2014, 64, 951-962.	1.6	82
29	Age and Ethnicity in Cirrhosis. <i>Journal of Investigative Medicine</i> , 2014, 62, 920-926.	0.7	36
30	New Paradigms in the Histopathology of NAFLD. <i>Current Hepatology Reports</i> , 2014, 13, 81-87.	0.4	0
31	Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease. <i>Hepatology</i> , 2014, 59, 471-482.	3.6	256
32	Risk of de novo post-transplant type 2 diabetes in patients undergoing liver transplant for non-alcoholic steatohepatitis. <i>BMC Gastroenterology</i> , 2015, 15, 175.	0.8	27
33	Increased risk of portal vein thrombosis in patients with cirrhosis due to nonalcoholic steatohepatitis. <i>Liver Transplantation</i> , 2015, 21, 1016-1021.	1.3	115
34	Clinical outcomes of cryptogenic compared with non-cryptogenic cirrhosis: A retrospective cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1423-1428.	1.4	5
37	Pathology of Non-Alcoholic Fatty Liver Disease. <i>International Journal of Digestive Diseases</i> , 2016, 2, .	0.2	10
38	Hepatocellular carcinoma in noncirrhotic livers is associated with steatosis rather than steatohepatitis: potential implications for pathogenesis. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 955-962.	0.8	14
40	The Effects of Alcohol on Other Chronic Liver Diseases. <i>Clinics in Liver Disease</i> , 2016, 20, 581-594.	1.0	13
41	Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 156-164.	3.7	116
43	Alcoholic and Non-Alcoholic Fatty Liver Disease. , 2016, , .		5
44	Pathology of Alcoholic and Nonalcoholic Fatty Liver Disease. , 2016, , 223-247.		4
45	Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1080-1086.	1.5	218
46	Histology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Adults and Children. <i>Clinics in Liver Disease</i> , 2016, 20, 293-312.	1.0	217

#	ARTICLE	IF	CITATIONS
47	Liver Transplantation for Nonalcoholic Steatohepatitis in the US: Temporal Trends and Outcomes. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2915-2922.	1.1	192
48	Characterization of transcriptional modules related to fibrosing-NAFLD progression. <i>Scientific Reports</i> , 2017, 7, 4748.	1.6	48
50	Prediction of histologic alcoholic hepatitis based on clinical presentation limits the need for liver biopsy. <i>Hepatology Communications</i> , 2017, 1, 1070-1084.	2.0	18
51	Multimodal LA-ICP-MS and nanoSIMS imaging enables copper mapping within photoreceptor megamitochondria in a zebrafish model of Menkes disease. <i>Metallomics</i> , 2018, 10, 474-485.	1.0	27
52	Systematic review with meta-analysis: de novo non-alcoholic fatty liver disease in liver-transplanted patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 704-714.	1.9	46
53	The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2018, 67, 328-357.	3.6	4,738
54	Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science. <i>Hepatology</i> , 2018, 67, 2001-2012.	3.6	125
55	Cryptogenic vs. NASH-cirrhosis: The rose exists well before its name..... <i>Journal of Hepatology</i> , 2018, 68, 391-392.	1.8	20
56	Liver Transplantation (LT) for Cryptogenic Cirrhosis (CC) and Nonalcoholic Steatohepatitis (NASH) Cirrhosis. <i>Medicine (United States)</i> , 2018, 97, e11518.	0.4	57
57	NASH-related and cryptogenic cirrhosis similarities extend beyond cirrhosis. <i>Journal of Hepatology</i> , 2018, 69, 972-973.	1.8	4
58	Fatty Liver Disease. , 2018, , 308-371.		14
59	Epidemiology of non-alcoholic fatty liver disease-related hepatocellular carcinoma and its implications. <i>JGH Open</i> , 2018, 2, 235-241.	0.7	47
62	Antioxidant Versus Pro-Apoptotic Effects of Mushroom-Enriched Diets on Mitochondria in Liver Disease. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3987.	1.8	21
63	Cryptogenic cirrhosis: Old and new perspectives in the era of molecular and genomic medicine. <i>Seminars in Diagnostic Pathology</i> , 2019, 36, 389-394.	1.0	5
64	Consenso mexicano de la enfermedad por hígado graso no alcohólico. <i>Revista De Gastroenterología De México</i> , 2019, 84, 69-99.	0.4	26
65	Pharmacologic Modulation of Bile Acid-FXR-FGF15/FGF19 Pathway for the Treatment of Nonalcoholic Steatohepatitis. <i>Handbook of Experimental Pharmacology</i> , 2019, 256, 325-357.	0.9	43
66	Comparison of the prevalence, severity, and risk factors for hepatic steatosis in HIV-infected and uninfected people. <i>BMC Gastroenterology</i> , 2019, 19, 52.	0.8	8
67	Characterization of HCC Mouse Models: Towards an Etiology-Oriented Subtyping Approach. <i>Molecular Cancer Research</i> , 2019, 17, 1493-1502.	1.5	23

#	ARTICLE	IF	CITATIONS
68	The Mexican consensus on nonalcoholic fatty liver disease. <i>Revista De GastroenterologÃa De MÃ©xico (English Edition)</i> , 2019, 84, 69-99.	0.1	6
69	Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 702-713.	1.9	28
70	Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 156-163.e2.	2.4	322
71	Epidemiological survey of hemoglobin A1c and liver fibrosis in a general population with nonalcoholic fatty liver disease. <i>Hepatology Research</i> , 2019, 49, 296-303.	1.8	29
72	Nonalcoholic Steatohepatitis After Liver Transplantation. <i>Liver Transplantation</i> , 2020, 26, 141-159.	1.3	49
73	Hepatic FATP5 expression is associated with histological progression and loss of hepatic fat in NAFLD patients. <i>Journal of Gastroenterology</i> , 2020, 55, 227-243.	2.3	29
74	Gender Matters: Characteristics of Hepatocellular Carcinoma in Women From a Large, Multicenter Study in the United States. <i>American Journal of Gastroenterology</i> , 2020, 115, 1486-1495.	0.2	27
75	Advances in ultrasound elastography for nonalcoholic fatty liver disease. <i>Journal of Medical Ultrasonics (2001)</i> , 2020, 47, 521-533.	0.6	17
76	Clinical and survival outcomes after hepatectomy in patients with non-alcoholic fatty liver and hepatitis B-related hepatocellular carcinoma. <i>Hpb</i> , 2021, 23, 1113-1122.	0.1	6
77	Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective?. <i>Cancers</i> , 2020, 12, 1422.	1.7	41
78	Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. <i>Gastroenterology</i> , 2020, 158, 1851-1864.	0.6	710
79	Incidence, aetiology and related comorbidities of cirrhosis: a Swedish population-based cohort study. <i>BMC Gastroenterology</i> , 2020, 20, 84.	0.8	30
80	NAFLD: Reporting Histologic Findings in Clinical Practice. <i>Hepatology</i> , 2021, 73, 2028-2038.	3.6	86
81	Liver stiffness measured by two-dimensional shear-wave elastography predicts hepatic vein pressure gradient at high values in liver transplant candidates with advanced liver cirrhosis. <i>PLoS ONE</i> , 2021, 16, e0244934.	1.1	6
82	Nineteen-year prognosis in Japanese patients with biopsy-proven nonalcoholic fatty liver disease: Lean versus overweight patients. <i>PLoS ONE</i> , 2020, 15, e0241770.	1.1	20
83	Recreational Drugs: a New Health Hazard for Patients with Concomitant Chronic Liver Diseases. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 23, 79-84.	0.5	13
84	Impact of hypothyroidism on the development of non-alcoholic fatty liver disease: A 4-year retrospective cohort study. <i>Clinical and Molecular Hepatology</i> , 2015, 21, 372.	4.5	47
85	Comparisons between non-alcoholic steatohepatitis and alcohol-related hepatocellular carcinoma. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 196-208.	4.5	15

#	ARTICLE	IF	CITATIONS
86	Pediatric non-alcoholic steatohepatitis: The first report on the ultrastructure of hepatocyte mitochondria. <i>World Journal of Gastroenterology</i> , 2014, 20, 4335.	1.4	36
87	Role of liver biopsy in nonalcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2014, 20, 9026-37.	1.4	166
88	Obesity and non-alcoholic fatty liver disease: Disparate associations among Asian populations. <i>World Journal of Hepatology</i> , 2014, 6, 263.	0.8	99
89	The Association of Nicotinamide Phosphoribosyltransferase Polymorphism with Markers of Hepatic Injury and De Novo Lipogenesis in Nonalcoholic Fatty Liver Disease. <i>Hepatitis Monthly</i> , 2017, 17, .	0.1	1
91	Prothrombotic and Inflammatory Markers in Elderly Patients with Non-Alcoholic Hepatic Liver Disease before and after Weight Loss: A Pilot Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 4906.	1.0	7
92	A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. <i>New England Journal of Medicine</i> , 2021, 385, 1547-1558.	13.9	284
93	Cryptogenic cirrhosis and NASH: entities in evolution and involution. <i>Tropical Gastroenterology: Official Journal of the Digestive Diseases Foundation</i> , 2014, 35, 65-70.	0.0	2
94	Clinical Manifestations of Liver Disease in Diabetes Mellitus. <i>Clinical Gastroenterology</i> , 2018, , 275-315.	0.0	0
95	Pathologic Diagnosis of Nonalcoholic Fatty Liver Disease. <i>Archives of Pathology and Laboratory Medicine</i> , 2022, 146, 940-946.	1.2	8
96	The Utility of Noninvasive PET/CT Myocardial Perfusion Imaging in Adult Liver Transplant Candidates. <i>Transplantation Direct</i> , 2022, 8, e1311.	0.8	6
97	Life Expectancy after Liver Transplantation for NASH. <i>Progress in Transplantation</i> , 2022, 32, 102-111.	0.4	4
98	Insights into Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis. <i>Medicina Interna (Bucharest, Romania: 1991)</i> , 2022, 19, 61-77.	0.1	0
99	Nonalcoholic fatty liver disease and health outcomes: An umbrella review of systematic reviews and meta-analyses. <i>Therapeutic Advances in Chronic Disease</i> , 2022, 13, 204062232210835.	1.1	2
100	Cryptogenic Cirrhosis. , 2022, , 475-488.		0
101	Fatty Liver Disease. , 2022, , 265-298.		0
102	La esteatohepatitis no alcoh�lica: una causa emergente de cirrosis en Colombia. <i>Revista Colombiana De Gastroenterologia</i> , 2022, 37, 136-144.	0.1	0
103	New horizon of ultrasound for screening and surveillance of non-alcoholic fatty liver disease spectrum. <i>European Journal of Radiology</i> , 2022, 154, 110450.	1.2	1
104	Advances in ultrasound elastography for nonalcoholic fatty liver disease. <i>Choonpa Igaku</i> , 2022, , .	0.0	0

#	ARTICLE	IF	CITATIONS
105	Work-up for Incidentally Detected NAFLD: How Far is It Worth?. Euroasian Journal of Hepato-gastroenterology, 2022, 12, S26-S36.	0.1	0
106	Non-alcoholic fatty liver disease: Definition and subtypes. Clinical and Molecular Hepatology, 2023, 29, S5-S16.	4.5	21
107	Artificial intelligence and deep learning: New tools for histopathological diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Computational and Structural Biotechnology Journal, 2023, 21, 2495-2501.	1.9	4
108	Resection of NAFLD/NASH-related Hepatocellular Carcinoma (HCC): Clinical Features and Outcomes Compared with HCC Due to Other Etiologies. Oncologist, 2023, 28, 341-350.	1.9	5
109	Predicting the outcome of liver transplantation in patients with nonalcoholic steatohepatitis cirrhosis: The NASH LT risk-benefit calculator. Clinical Transplantation, 2023, 37, .	0.8	1
110	Fatty Liver Disease. , 2024, , 330-401.		1
111	Ethnic disparities in waitlist outcomes of patients with nonalcoholic steatohepatitis listed for liver transplantation in the US. Liver Transplantation, 2023, 29, 1181-1191.	1.3	1
112	Morphopathology of Nonalcoholic Fatty Liver Disease. , 2023, , 89-98.		0